Screener
Acadia Pharmaceuticals ACAD Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Intangible assets, net | 103,448 | 108,893 |
| Restricted cash | 7,846 | 7,845 |
| Long-term inventory | 76,301 | 76,704 |
| Deferred tax assets | 240,679 | 249,879 |
| Other assets | 3,550 | 3,896 |
| Total assets | $1,742,900 | $1,564,195 |
| Liabilities and stockholders’ equity | ||
| Accounts payable | $44,566 | $10,903 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's deferred tax assets?
- Acadia Pharmaceuticals (ACAD) reported deferred tax assets of $240.68M in Q2 2026.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.
Ask your AI about Acadia Pharmaceuticals's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude